Renal carcinoma accounts for 2 to 3% of all adult malignancies worldwide. Five-year survival rates in Poland are approximately 58% for both sexes. More than 70% of cases are diagnosed at an early stage. However, the remaining patients develop metastases to the lungs, liver, bones, adrenal glands or the other kidney. Cutaneous location is rare. Skin metastases account for approximately 6% of cases and have a poor prognosis. Invasive cutaneous renal cell carcinoma involving the scalp, neck, trunk, limbs and genitals has been reported in the literature. This paper presents a case of a 73-year-old man with renal carcinoma invading the skin of the cheek. The post-nephrectomy follow up includes, depending on the risk group, thoracic and abdominal computed tomography, as well as abdominal ultrasound. In this case, the tumour was found to be a metastasis, among others, to the lungs, chest lymph nodes, and the other kidney. There was no regression of the cheek metastasis after one cycle of palliative immunotherapy with ipilimumab in combination with nivolumab. The patient did not survive until the next cycle due to progression of lung metastases. According to the literature and the case described above, metastases of renal carcinoma may appear both shortly after the diagnosis and at a distant time. Typically, they occur as a single, rapidly growing tumour in any cutaneous location, which, however, is accompanied by cancer spread (single or multiple) to other organs. Therefore, given the available therapeutic options, such as the use of tyrosine kinase inhibitors, regular patient monitoring is essential. This should include not only imaging and laboratory tests, but also a thorough history focused on unusual symptoms, careful skin examination, and a decisive, prompt response to any suspicious abnormalities.